Ven­ture fund starts an­ti­body biotech in Delaware; CRO changes pri­vate eq­ui­ty hands

On Mon­day, a Lux­em­bourg ven­ture fund an­nounced their in­vest­ment of an undis­closed amount in­to es­tab­lish­ing a mon­o­clon­al an­ti­body-fo­cused biotech. The biotech has no web­site, but it has a name, a lo­ca­tion and a CEO: T7 Ther­a­peu­tics, based out of Wilm­ing­ton, Delaware — head­ed by Car­o­line Forti­er.

The fund, TVM Cap­i­tal Life Sci­ence, made the an­nounce­ment in con­junc­tion with Nekon­al S.a.r.l, a Lux­em­bourg biotech which helped play a role in some of the ear­ly sci­ence that T7 will be fo­cus­ing on.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER